COVID-19-Related Inhibitors

Small molecule inhibitors that are able to block entry, replication or subsequent host immune responses induced by SARS-CoV-2 (2019-nCoV) are of great interest in investigating therapeutic strategies to treat and prevent Coronavirus Disease-2019 (COVID-19). InvivoGen offers a selection of inhibitors known to act at different stages of the infection.


Endosomal acidification inhibitors

Targets of COVID-19-Related inhibitors
Targets of COVID-19-Related inhibitors

Coronaviruses, such as SARS-CoV and presumably SARS-CoV-2, enter and are trafficked through the host cell in endosomes. Targeting and blocking endosomal acidification may help further study how SARS-CoV-2 infects host cells.

Viral RNA-dependent RNA polymerase inhibitor

The targeting of the viral RNA-dependent RNA-polymerase (RdRp), essential for viral replication, has been promising in the clinic for the treatment of COVID‑19. Understanding how SARS-CoV-2 replicates is imperative in developing targeted and effective therapeutics.

JAK/STAT signaling inhibitor

Activation of the JAK/STAT pathway by type I IFNs amplifies their action through the production of a plethora of IFN-stimulated genes. However, in the case of COVID‑19, this can lead to hyper-inflammation and ultimately to a cytokine storm. Inhibiting this pathway will help further investigations into the COVID‑19 associated cytokine storm.


InvivoGen’s products are for research use only, and not for clinical or veterinary use.



Customer Service
& Technical Support
Contact us
Shopping cart is empty